-
公开(公告)号:US20230257426A1
公开(公告)日:2023-08-17
申请号:US18139003
申请日:2023-04-25
Inventor: Sangyong JON , Sukmo KANG , Yujin KIM , Ji-Joon SONG
CPC classification number: C07K14/23 , C07K14/11 , C12N15/63 , A61K39/02 , A61K39/145 , A61P37/04 , A61K2039/10
Abstract: The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.
-
2.
公开(公告)号:US20230355513A1
公开(公告)日:2023-11-09
申请号:US18219956
申请日:2023-07-10
Inventor: Sangyong JON , Afia Tasnim RAHMAN , Chang-Hee WHANG
CPC classification number: A61K9/0053 , A61P1/00 , C08B37/003 , A61K31/409 , A61K47/6939 , A61P29/00
Abstract: The present disclosure relates to: a chitosan-bilirubin conjugate; particles; and an oral pharmaceutical composition including same. The conjugate and/or particles according to the present disclosure have excellent antioxidant and anti-inflammatory effects, exhibit systemic inflammation relieving effects as well as intestinal inflammatory reaction relieving effects, and have the effect of normalizing the balance of intestinal microflora distribution, and thus, can be useful for treating inflammatory bowel diseases, systemic and chronic inflammatory diseases, etc.
-